A randomized clinical trial on the effects of bupropion and buprenorphine on the reduction of methamphetamine craving
Open Access
- 30 July 2019
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-7
Abstract
The purpose of this study was to compare the effect of 300 mg of bupropion and 8 mg of buprenorphine per day on the treatment of methamphetamine withdrawal cravings over a 2-week treatment interval. Sixty-five methamphetamine-dependent men who met the DSM-IV-TR (Diagnostic and Statistical Manual of Mental Disorders, 4th edition, text revision) criteria for methamphetamine dependence and withdrawal were randomly divided into two groups. Subjects randomly received 300 mg of bupropion or 8 mg of buprenorphine per day in a psychiatric ward. Of the 65 subjects, 35 (53.8%) received buprenorphine and 30 (46.2%) received bupropion. The subjects were assessed by using methamphetamine craving score, interview, and negative urine drug test. There were no statistically significant differences between the two groups in regard to age, education, duration of methamphetamine dependency, marital status, employment, and income. The mean ages were 32.8 years (standard deviation (SD) = 7.26, range = 22 to 59) for the buprenorphine group and 32.21 years (SD = 8.45, range = 17 to 51) for the bupropion group. All 65 patients completed the 2-week study. Both medications were effective in the reduction of methamphetamine cravings. Reduction of craving in the buprenorphine group was significantly more than the bupropion group (P = 0.011). Overall, a significant main effect of day (P 0.05) were detected. The results support the safety and effectiveness of buprenorphine and bupropion in the treatment of methamphetamine withdrawal craving. Administration of 8 mg of buprenorphine per day can be recommended for the treatment of methamphetamine withdrawal cravings. We should note that it is to be expected that craving decreases over time without any medication. So the conclusion may not be that bupropion and buprenorphine both lower the craving. As the buprenorphine is superior to bupropion, only buprenorphine does so for sure. Iranian Registry of Clinical Trials (IRCT) registration number: IRCT2015010320540N1 . Date registered: April 10, 2015.Keywords
Funding Information
- Shiraz University of Medical Sciences (IR.SUMS.REC.92-01-01-6693))
This publication has 32 references indexed in Scilit:
- Crystal structure of the µ-opioid receptor bound to a morphinan antagonistNature, 2012
- Efficacy of continuing medical education to reduce the risk of buprenorphine diversionJournal of Substance Abuse Treatment, 2011
- Methamphetamine Induced Synesthesia: A Case ReportThe American Journal on Addictions, 2011
- Expanding treatment capacity for opioid dependence with office-based treatment with buprenorphine: National surveys of physiciansJournal of Substance Abuse Treatment, 2010
- Intravenous Misuse of BuprenorphineClinical Drug Investigation, 2010
- Pharmacy Willingness to Partner with Office-Based Opioid Dependence Treatment Providers in Conducting Random Buprenorphine Pill CountsThe American Journal on Addictions, 2010
- Predictors of Treatment Outcome in Outpatient Cocaine and Alcohol Dependence TreatmentThe American Journal on Addictions, 2009
- Cocaine Withdrawal Symptoms Identify “Type B” Cocaine‐Dependent PatientsThe American Journal on Addictions, 2008
- Attentional Control and Brain Metabolite Levels in Methamphetamine AbusersBiological Psychiatry, 2007
- SUBSTANCE USE AMONG IRANIAN PSYCHIATRIC INPATIENTSPsychological Reports, 2001